Evidence map›Paper›PMID 40857214›Full record

ArticleMycoses2025

Appearance of Environment-Linked Azole Resistance in the Aspergillus fumigatus Complex in New Zealand.

Arthur J Morris, Wendy P McKinney, Sally A Roberts, Sasiharan Sithamparanathan, Zain Chaudhry, Matthew C Fisher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mycoses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arthur J MorrisNew Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland, New Zealand.ORCID https://orcid.org/0000-0002-0860-7187
Wendy P McKinneyNew Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland, New Zealand.
Sally A RobertsNew Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland, New Zealand.
Sasiharan SithamparanathanRespiratory Medicine and New Zealand Lung Transplant Service, Auckland City Hospital, Auckland, New Zealand.
Zain ChaudhryDepartment of Infectious Disease Epidemiology, Imperial School of Public Health, London, UK.
Matthew C FisherDepartment of Infectious Disease Epidemiology, Imperial School of Public Health, London, UK.ORCID https://orcid.org/0000-0002-1862-6402

Funding

Canadian Institute for Advanced ResearchUK MRC MR/X020258/1UK Natural Environment Reasearch CouncilWellcome TrustWellcome Trust 219551/Z/19/Z
6 · The paper itself

Abstract

backgroundUntil 2020, azole resistance in Aspergillus fumigatus complex isolates in New Zealand was due to cyp51A hot spot mutations. This report details the appearance of environment-linked tandem repeat (TR)-related azole resistance genotypes since 2021.

methodsIsolates were tested by broth micro-dilution. Clinical Laboratory Standards Institute criteria were used to define wild type (WT) and non-wild type (non-WT) isolates, which were identified by ß-tubulin gene sequencing and had their cyp51A genotype for azole resistance determined. Whole genome sequencing (WGS) was applied to two patient pairs of sequential WT and non-WT isolates.

resultsFrom January 2021 to June 2024, 15 of 147 (10.2%) A. fumigatus complex isolates were resistant or non-WT for one or more azole agents. Genotyping detected hot spot mutations in four and TR-associated resistance in nine. No mutations were detected in two isolates. Four of the five TR

conclusionsA. fumigatus sensu stricto isolates with TR-mutations linked to environmental resistance are now present in New Zealand. Those at risk of invasive A. fumigatus infection should receive advice to avoid high-risk exposures. Reintroducing monitoring of azole-containing fungicides is recommended.

Indexed as

Antifungal AgentsAspergillus fumigatusAzolesDrug Resistance, FungalAspergillosisCytochrome P-450 Enzyme SystemFemaleFungal ProteinsGenotypeHumansMaleMicrobial Sensitivity TestsMutationNew ZealandTandem Repeat SequencesTubulinAntifungal AgentsAzolescytochrome P-450 CYP51A, AspergillusCytochrome P-450 Enzyme SystemFungal ProteinsTubulinantifungal resistanceantifungal treatmentAspergillus fumigatusazolesECVsgenotypenon‐wild typeresistance mechanismswild‐type

Identifiers

PMID40857214
PMCPMC12379841

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.